Clinical & Scientific

Early trial data for ABX1100 reveals a novel approach to reducing muscle damage in Pompe disease, offering hope for less burdensome treatment.

After a blockbuster IPO raised nearly $300 million, dermatologist-founded Veradermics is poised to challenge the hair loss market with its new oral pill.

A new partnership aims to overcome the hurdles of at-home testing by combining instrument-free PCR with advanced enzymes for rapid, reliable results.

With backing from top VCs, Angitia Biopharmaceuticals is accelerating its novel treatments for osteoporosis and rare bone disorders. Here's why it matters.

Initial results from a deep exploration project at Quebec's Gaspé Copper mine reveal a massive, high-grade copper zone, signaling a new chapter for the region.

Everest Medicines bets big on MT1013, a novel dual-action drug poised to transform treatment for millions with chronic kidney disease complications.

A simple nasal spray could offer immediate, broad protection against the flu. New landmark studies show how this antibody-based shield could revolutionize prevention.

With a fresh capital infusion extending its runway into 2027, GRI Bio pushes ahead with promising clinical data for its IPF and autoimmune disease pipeline.

CoSara Diagnostics' ISO 13485 certification paves the way for regulatory approval of a new PCR platform, leveraging India's 'Make in India' initiative.

Beyond Cancer is set to reveal early human trial data for its novel nitric oxide therapy, a move that could expand its parent company into oncology.

Celcuity prepares for a key fireside chat at Guggenheim's 2026 summit, with investors eyeing crucial updates on its lead cancer drug, gedatolisib.

A new class of compounds 'disarms' TB bacteria instead of killing it, a breakthrough that could help defeat drug resistance and treat the world's deadliest disease.

After flawless human trials, a Chapel Hill startup secures funding to bring its revolutionary ultrasound-based blood clot treatment to the United States.

At a critical juncture, Abcourt Mines brings a long-time consultant in-house, betting his expertise can overcome financial hurdles and unlock project value.

vTv Therapeutics shores up its finances with a deal worth up to $135M, sharpening its focus on a breakthrough Type 1 diabetes drug, cadisegliatin.

With a major Phase 3 trial now in Europe, Crystalys Therapeutics aims to fill a critical gap in gout care with a drug already proven in Asian markets.

A new platform, Accelerated Clinical Trials (ACT), promises to slash drug development timelines by up to 20 months, but faces regulatory and ethical hurdles.

Mwyngil Therapeutics starts clinical trials for a novel brain-penetrating drug, aiming to tackle neuroinflammation at its source in MS and Parkinson's.

The Spanish biotech firm strengthens its IP for a novel aggression treatment, targeting a growing multi-billion dollar Japanese CNS market.

NurExone appoints Eyal Gabbai, a healthcare and finance heavyweight, to its board, signaling a strategic pivot from R&D to market execution for its therapies.